ICU Medical Stock Market Outlook

Stocks . USA . 
Stock . ICU Medical
ICUI Stock  USD 126.48  0.05  0.04%   
The ratio of positive to negative mentions in recent coverage offers a snapshot of where public discussion currently leans, but the reading remains only one part of the overall model. About 64% of recent sentiment around ICU Medical has leaned defensive over the recent sample. Taken on its own, that leaves the current sentiment reading for ICU Medical below neutral at this time.
Investor Comfort Level
PanicConfidence
36 · Alarmed

Elasticity to Hype and News Sentiment

Tracking ICU Medical positive news sentiment (74%) is particularly informative when headlines and price behavior start diverging. Shifts in news tone at this level often precede a change in trading character that warrants attention.
Given a 90-day horizon, with a highly speculative risk level, the model output for ICU Medical is 'Hold'. The directional recommendation for ICU Medical is produced by a quantitative model processing multiple data inputs. Market positioning data and performance patterns are combined to generate the signal. Macroaxis buy or sell analysis combines algorithmic processing with current market condition assessment. This signal serves as one input among several in the investment decision-making process.
  

Run ICU Medical Outlook Model

The ICU Medical model signal below complements and cross-checks analyst coverage of ICU Medical. Macroaxis is fully independent and carries no interest in ICU Medical or related covered assets. The ICU Medical's module uses market data together with historical trend analysis. This quantitative perspective adds context to analyst commentary on ICU Medical.

How This Model Works

The recommendation output for ICU Medical is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.

  • Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
  • Current setup - Three Months with a risk setting described as I love taking a lot of risk
  • Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates

Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.

Time Horizon

Risk Tolerance

Update Outlook
SellBuy
Hold

Market Performance

WeakDetails

Volatility

Very LowDetails

Current Valuation

Below Model EstimateDetails

Odds Of Distress

MinimalDetails

Economic Sensitivity

Actively responds to the marketDetails

Investor Sentiment

AlarmedDetails

Analyst Consensus

Strong BuyDetails

Financial Strenth (F Score)

HealthyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

Unlikely ManipulatorDetails
ICU Medical's current outlook reflects mixed signals, where recent market performance has undercut momentum, while contained volatility and intact fundamental quality provide partial offset. The model's 'Hold' signal reflects mixed signals where neither bullish nor bearish factors dominate. A Hold indicates that neither bullish nor bearish factors dominate across the model inputs, producing a balanced but inconclusive reading. For the selected horizon, ICU Medical yields Risk Adjusted Performance of -0.09, Jensen Alpha of -0.24, and Total Risk Alpha of -0.24, which produce a balanced but non-directional signal.
This quantitative reading for ICU Medical is derived from a multi-factor model that evaluates current market conditions, fundamental quality, and momentum alongside the expert outlook. For additional context on this mid-cap stock in the Health Care sector, assess the full set of ICU Medical reported fundamentals, including the relationship between the total debt ttm and trailing beta. With a price to earnings ttm of 38.71 X. ICU Medical's market performance and bankruptcy risk are relevant reference points going forward.

Recent Events and Market Context

The events below reflect recent headlines associated with ICU Medical. Not all items directly affect the outlook โ€” they are included to show the broader information environment that can shape sentiment and trading behavior.

Returns Distribution Density

For ICU Medical, this chart shows how daily price changes have been distributed. The width of the curve reflects aggregate price volatility for ICU Medical. Value At Risk captures the downside tail and Upside Potential captures the upside. The center is the most frequent outcome while the tails show how extreme the swings have been historically.
Mean Return
-0.23
Value At Risk
-3.87
Potential Upside
3.25
Standard Deviation
2.33
   Return Density   
       Distribution  
How extreme have ICU Medical's daily price moves been historically? The return chart below shows exactly that for ICU Medical. It allows side-by-side comparison of risk-return profiles on a risk-adjusted basis. The tails of ICU Medical's return distribution are where the most consequential risk information lies.

Top Institutional Investors

At mid-cap scale, institutional coverage and secondary-market liquidity are typically well established. The holder split in ICU Medical separates passive index allocation from active institutional positioning. The business currently sits in the Health Care sector and the Health Care Equipment & Services industry. Volume spikes around index rebalance dates warrant attention given the high institutional share.
Shares
Jpmorgan Chase & Co2025-12-31
529.1 K
Morgan Stanley - Brokerage Accounts2025-12-31
518.6 K
Norges Bank2025-12-31
407.1 K
Silvercrest Asset Management Group Llc2025-12-31
380.5 K
Fmr Inc2025-12-31
362.5 K
Defilade Capital Management, L.p.2025-12-31
340.7 K
Northern Trust Corp2025-12-31
338.8 K
Point72 Asset Management, L.p.2025-12-31
337.7 K
Charles Schwab Investment Management Inc2025-12-31
309.6 K
Blackrock Inc2025-12-31
3.6 M
Vanguard Group Inc2025-12-31
2.7 M
For a mid-cap like ICU Medical (3.16 billion), benchmark pressure and redemption cycles can limit how institutional weight turns into price support. Whether ICU Medical institutional base is index-driven or conviction-based changes how to read it - at this size active managers often hold meaningful weight.

Cash Flow Accounts

20222023202420252026 (projected)
Dividends Paid1.0M10.9M9.4M10.8M11.3M
Backtest ICU Medical

Key Drivers of Volatility and Market Exposure

ICU Medical exhibits both macro-linked volatility and company or sector-specific developments. Beta and standard deviation quantify relative market risk. ICU Medical reported a Mean Deviation of 1.92 and a Standard Deviation of 2.33.
α
Alpha over Dow Jones		-0.2381
β
Beta against Dow Jones1.64
σ
Overall volatility		2.32
Ir
Information ratio -0.1027
ICU Medical standard deviation quantifies total return variability. With a beta of 1.6433, ICU Medical tends to move more sharply than the market during both rallies and selloffs. ICU Medical Sharpe ratio stands at -0.1173, signaling that volatility has not been rewarded with positive excess returns.

Fundamentals Vs Peers

Relative fundamental analysis for ICU Medical puts the stock's operating metrics in a competitive context. Peer comparison for ICU Medical converts standalone metrics into a relative ranking that sharpens the investment case. ICU Medical's financial indicators tested against comparable stocks identify which metrics are driving relative valuation. Peer analysis extends standalone financial analysis for ICU Medical into a competitive framework.
    
 Better Than Average     
    
 Worse Than Average Compare ICU Medical to competition
FundamentalsICU MedicalPeer Average
Return On Equity TTM0.0226-0.31
Return On Asset TTM0.0168-0.14
Profit Margin TTM0.0215-1.27
Operating Margin TTM0.0573-5.51
Current Valuation4.2 B16.62 billion
Shares Outstanding24.99 M571.82 million
Shares Owned By Insiders3.78 %10.09 %
Shares Owned By Institutions96.22 %39.21 %
Number Of Shares Shorted1.3 M4.71 million
Price To Earnings TTM38.71 X28.72 X
Price To Book TTM1.50 X9.51 X
Price To Sales TTM1.47 X11.42 X
Revenue TTM2.23 B9.43 billion
Gross Profit TTM818.16 M27.38 billion
EBITDA TTM326.54 M3.9 billion
Net Income TTM732 K570.98 million
Cash And Equivalents TTM285.59 M2.7 billion
Cash Per Share TTM11.95 X5.01 X
Total Debt TTM1.39 B5.32 billion
Debt To Equity TTM0.84 %48.70 %
Current Ratio TTM2.45 X2.16 X
Book Value Per Share TTM86.03 X1,931
Cash Flow From Operations TTM179.85 M971.22 million
Short Ratio TTM4.63 X4.00 X
Earnings Per Share1.86 X3.12 X
Price To Earnings To Growth0.08 X4.89 X
Target Price174.17N/A
Number Of Employees13 K18,840
Trailing Beta0.74-0.15
Market Capitalization TTM3.16 B19.03 billion
Total Asset TTM4.05 B29.47 billion
Retained Earnings TTM690.89 M9.33 billion
Working Capital TTM691.69 M1.48 billion
Note: Acquisition by Virginia Sanzone of 2348 shares of ICU Medical subject to Rule 16 b-3 [view details]

Market Momentum

ICU Medical neutral RSI of 48 combined with high-beta sensitivity (1.6433) reveals whether current momentum is driven by company-specific demand or market-wide flows. The company operates within the Healthcare sector and the Medical Instruments & Supplies industry. Together, these momentum and sensitivity readings help investors judge whether a position adjustment or patience is warranted.
Accumulation Distribution0.056
Daily Balance Of Power0.0068
Rate Of Daily Change1.0
Day Median Price126.72
Day Typical Price126.64
Market Facilitation Index7.3
Price Action Indicator-0.21
Period Momentum Indicator0.05
Relative Strength Index48.15

Current Target Price Consensus

All tracked analyst projections for ICU Medical are averaged to produce a consensus target price. Assessing analyst performance is complex and relies on comparing predictions to historical outcomes. ICU Medical's target price estimates gain depth when combined with other prediction tools including sentiment analysis. Combining ICU Medical's target price data with traditional prediction techniques supports more informed analysis.
   6  Strong Buy
Analysts covering ICU Medical generally publish new ratings at three-month intervals. A target price is provided to help investors understand the gap between ICU Medical's market price and estimated intrinsic value. Analysts base their conclusions on ICU Medical's published financials, management discussions, and industry research. These professionally researched ratings serve as one input in a broader ICU Medical analysis.
Exposure   Valuation

ICU Medical Target Price Projection

As of the latest data, ICU Medical is trading at 126.48 with an analyst consensus target of 174.17. ICU Medical's current price reflects the balance of buying and selling pressure, whereas the target is a forward-looking estimate. A large discrepancy between the two can be a catalyst for investor activity. The gap between market price and analyst target is one of the most direct signals available for ICU Medical.

Current Price

ICU Medical Market Quote on 11th of May 2026

Low Price123.07Odds
High Price130.37Odds

126.48

Target Price

Analyst Consensus On ICU Medical Target Price

Low Estimate158.49Odds
High Estimate193.33Odds

174.17

Historical Lowest Forecast  158.49 Target Price  174.17 Highest Forecast  193.33
Price targets for ICU Medical are typically published within formal analyst research reports. Since financial news outlets often cite these targets, a potential brief delay merits attention. The latest analyst projection for ICU Medical may not be available here immediately upon publication. This timing consideration is standard for analyst-sourced data across stock coverage.

ICU Medical Analyst Ratings

Right now, 6 analysts rate ICU Medical with an aggregate Strong Buy consensus. Strong Buy is the most common call among 6 analysts at 3 votes. Strong Buy represents the prevailing view among those covering ICU Medical. See below for how ratings have moved over recent months.

Analyst Consensus Breakdown

Average Consensus Estimates

Recommendation Framework, Assumptions & Editorial Oversight

The model output for ICU Medical reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for ICU Medical include P/E of 38.71, ROE of 2.26%. External analyst coverage is currently summarized as Strong Buy across 6 analysts, but it is treated here as a secondary reference input rather than a stand-alone recommendation. Published target-price assumptions may also be reviewed when available, but they can change quickly as analyst models are revised.

ICU Medical analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.

Editorial Review & Methodology Oversight

Michael Smolkin
Role: Member of Macroaxis Board of Directors
Finance background: Michael joined Macroaxis in August of 2020 after several months of consulting for the company on financial matters regarding the post-pandemic world and upcoming inflation. In his investing and articles, Michael focuses his analyses on inflation, data processing and its role in AI/ML, FinTech, and the surprising parallels that arise between neurobiology and finance.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.
Last reviewed on April 23rd, 2026

Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.